An international team of researchers from Adelaide and the United States has engineered bacteria capable of detecting mutated DNA released from colorectal cancer cells, opening the door to faster disease detection.
Led by Dr Dan Worthley, Associate Professor Susan Woods and Dr Josephine Wright from SAHMRI and the University of Adelaide, in partnership with Professor Jeff Hasty at the University of California San Diego (UCSD), the study was published today in the prestigious journal, Science.
The team engineered bacteria called Acinetobacter baylyi (A. baylyi), which is known for its ability to sample and integrate DNA from its environment. Researchers leveraged this natural competence to detect the mutated KRAS gene, an important driver of colorectal cancer.
A/Prof Woods says they dubbed this technology ‘CATCH’, which stands for, Cellular Assay of Targeted CRISPR-discriminated Horizontal gene transfer.
“CATCH has the potential to detect bowel cancer early with the aim of preventing more people from dying of this and other cancers,” she said.
“This study demonstrates how bacteria can be designed to detect specific DNA sequences to diagnose disease in hard-to-reach places.”
In preclinical testing, the team found that the sensor bacteria were 100% accurate in differentiating between models with and without colorectal cancer.
“We were thrilled to see transfer of DNA from the tumour to the sensor bacteria,” A/Prof Woods said.
“This shows that our biosensing system can be used to catch colorectal cancer DNA within a complex ecosystem.”
Dr Dan Worthley says potential applications of the technology extend beyond cancer.
“In the future we will detect and prevent many diseases, including bowel cancer, with cells, not drugs,” he said.
“We hope that this invention, of life detecting life, will be useful for clinicians, scientists and engineers to help the community wherever and whenever DNA detection is important.”.
While further studies are needed before progressing to clinical trials, researchers are confident this latest discovery represents a significant advance in the field of living diagnostics while setting the stage for the timely and accurate delivery of targeted treatments.
-
Infections and other lung diseases using models of human lung tissue grown from stem cells
Dr Rhiannon Werder is a Team Leader at Murdoch Children’s Research Institute leading a multidisciplinary team, combining expertise in stem cell biology and immunology, to develop new therapies for lung diseases. Her research centres around induced pluripotent stem cells to investigate respiratory diseases, spanning acute respiratory infections to chronic lung diseases. Using stem cells, Dr Werder’s team creates models of human lung tissue. With these models, Dr Werder is investigating how human-specific pathogens infect different regions of the lung, the ensuing immune responses, and how the lung repairs itself after infections, especially in people with preexisting lung diseases.
-
Professor Christoph Hagemeyer
RESEARCH IN NANOBIOTECHNOLOGY
@ MONASH UNIVERSITY
VICTORIA, AUSTRALIA -
RESEARCH IMPACT SAHMRI, SOUTH AUSTRALIA (2023)
South Australian Health and Medical Research Institute, also known as SAHMRI has had significant impacts in various areas over the past ten years, and this year is celebrating its 10 year anniversary with a week of events.
Ahead of the anniversary, Executive Director, Professor Maria Makrides spoke to Bench Side Story about 3 achievements in the past 10 years that have had significant impact
